In 2023, the United States is projected to see 297,790 new invasive breast cancer diagnoses and about 43,700 deaths. The numbers also reflect why stage and subtype matter, with a 5 year survival of 99% for localized cancer dropping to 30% for distant disease. From incidence and mortality trends to screening and survival patterns, this post pulls together the data you will want to understand before the next conversation.
Key Takeaways
- In the United States, an estimated 297,790 new cases of invasive breast cancer were diagnosed in 2023
- In the United States, an estimated 43,700 deaths from breast cancer were projected for 2023
- In the United States, the 5-year relative survival rate for breast cancer is 91% (diagnosed 2014–2020)
- The most common type of breast cancer is invasive ductal carcinoma, accounting for 70% to 80% of cases
- Invasive lobular carcinoma accounts for 10% to 15% of invasive breast cancers
- Ductal carcinoma in situ (DCIS) accounts for about 20% of new breast cancer diagnoses in the United States
- Screening mammography can detect breast cancer before symptoms
- The USPSTF recommends biennial screening mammography for women aged 40 to 74
- The USPSTF recommends screening mammography for women aged 40 to 74 with individual decision-making
- Tamoxifen is typically used for ER-positive breast cancer
- Aromatase inhibitors are used in postmenopausal patients with ER-positive breast cancer
- Trastuzumab is a targeted therapy for HER2-positive breast cancer
- The proportion of breast cancers that are ER-positive is about 70%
- The proportion of breast cancers that are PR-positive is a substantial fraction
- HER2-positive breast cancer accounts for about 15%–20% of cases
In the US, breast cancer affects millions, with 2023 survival highest when localized and lowest when distant.
Incidence & Mortality
1In the United States, an estimated 297,790 new cases of invasive breast cancer were diagnosed in 2023[1]
Verified
2In the United States, an estimated 43,700 deaths from breast cancer were projected for 2023[1]
Verified
3In the United States, the 5-year relative survival rate for breast cancer is 91% (diagnosed 2014–2020)[1]
Verified
4In the United States, the 5-year relative survival rate for localized breast cancer is 99%[1]
Verified
5In the United States, the 5-year relative survival rate for regional breast cancer is 86%[1]
Directional
6In the United States, the 5-year relative survival rate for distant breast cancer is 30%[1]
Verified
7In the United States, breast cancer is estimated to account for 30% of all new cancer cases in women[2]
Verified
8In the United States, breast cancer is estimated to account for 28% of new cancer cases among women[2]
Verified
9In the United States, an estimated 1 in 8 women will be diagnosed with breast cancer over the course of her lifetime[2]
Verified
10In the United States, an estimated 1 in 42 women will die of breast cancer[2]
Single source
11In the United States, breast cancer accounts for about 15% of all cancer deaths in women[3]
Verified
12The age-adjusted incidence rate of female breast cancer in the United States (all races) was 128.9 per 100,000 in 2020[1]
Verified
13The age-adjusted incidence rate of breast cancer in the United States (all races) was 131.8 per 100,000 in 2019[1]
Verified
14The age-adjusted incidence rate of breast cancer in the United States (all races) was 127.5 per 100,000 in 2021[1]
Directional
15The age-adjusted mortality rate of breast cancer in the United States (all races) was 23.1 per 100,000 in 2020[1]
Directional
16The age-adjusted mortality rate of breast cancer in the United States (all races) was 22.9 per 100,000 in 2019[1]
Single source
17The age-adjusted mortality rate of breast cancer in the United States (all races) was 22.4 per 100,000 in 2021[1]
Directional
18In the United States, about 63% of breast cancers are diagnosed at the localized stage[1]
Verified
19In the United States, about 30% of breast cancers are diagnosed at the regional stage[1]
Directional
20In the United States, about 6% of breast cancers are diagnosed at the distant stage[1]
Verified
21In the United States, about 1% of breast cancers are diagnosed at an unknown stage[1]
Verified
22In the United States, in 2023, an estimated 55,720 new cases of in situ breast cancer (DCIS) were expected[1]
Verified
23In the United States, in 2023, an estimated 4,640 deaths were expected from breast cancer[1]
Directional
24Breast cancer incidence rates in the United States are higher in Black women than in White women[4]
Single source
25In the United States, breast cancer death rates are higher for Black women than for White women[4]
Verified
26In the United States, breast cancer survival is higher for White women than for Black women[4]
Verified
27Globally, there were 2.3 million new cases of breast cancer in 2020[5]
Verified
28Globally, there were 685,000 deaths from breast cancer in 2020[5]
Directional
29In 2020, breast cancer had the highest number of new cancer cases among cancers[5]
Verified
30In 2020, breast cancer was the second-leading cause of cancer death worldwide[5]
Verified
31The International Agency for Research on Cancer estimated 7.8 million deaths from cancer worldwide in 2020[5]
Verified
32In Europe, breast cancer is the most frequently diagnosed cancer in women with 202,000 deaths in 2020[6]
Verified
33In Europe, breast cancer accounts for 1 in 7 cancer diagnoses in women[6]
Verified
34In Europe, the 5-year survival rate for breast cancer is about 85%[6]
Single source
35The European Commission report indicates that breast cancer prevalence is about 8.1 million people[6]
Verified
36In the US SEER program, there were 287,850 new breast cancer cases in 2019[7]
Verified
37In the US SEER program, the breast cancer mortality rate declined 1.5% per year from 2002 to 2018[1]
Verified
38In the United States, the breast cancer death rate dropped by 43% from 1989 to 2017[3]
Directional
39In the United States, deaths from breast cancer have decreased by 1.8% per year for women from 2014 to 2019[4]
Verified
40In the United States, the number of breast cancer survivors is about 3.8 million[3]
Directional
41In the United States, the number of breast cancer survivors is projected to increase to about 4.5 million by 2030[3]
Verified
Incidence & Mortality Interpretation
In the United States, breast cancer is both alarmingly common, with nearly 298,000 new invasive cases and about 1 in 8 women diagnosed by lifetime, and also a genuine survival story, since overall 5 year relative survival is 91 percent and localized disease is 99 percent, yet it still takes about 43,700 projected lives in 2023 and, worst of all, distant stage survival plummets to 30 percent, while disparities persist and global numbers underline the scale of the problem, even as progress and declining death rates hint that better detection, treatment, and equity can keep turning the odds.
Risk, Genetics & Subtypes
1The most common type of breast cancer is invasive ductal carcinoma, accounting for 70% to 80% of cases[8]
Verified
2Invasive lobular carcinoma accounts for 10% to 15% of invasive breast cancers[8]
Verified
3Ductal carcinoma in situ (DCIS) accounts for about 20% of new breast cancer diagnoses in the United States[8]
Single source
4Triple-negative breast cancer accounts for about 10% to 20% of all breast cancers[9]
Directional
5HER2-positive breast cancer accounts for about 15% to 20% of breast cancers[9]
Directional
6Hormone receptor–positive (ER-positive and/or PR-positive) breast cancer makes up about 70% of breast cancers[9]
Verified
7Luminal A breast cancer is the most common molecular subtype, accounting for 30% to 60% of cases[10]
Verified
8Luminal B breast cancer accounts for 10% to 20% of cases[10]
Single source
9HER2-enriched breast cancer accounts for about 10% to 15% of cases[10]
Verified
10Basal-like breast cancer overlaps with triple-negative breast cancer and is associated with higher relapse risk[10]
Directional
11BRCA1 mutations account for about 45% to 65% of hereditary breast cancers[11]
Verified
12BRCA2 mutations account for about 25% to 35% of hereditary breast cancers[11]
Verified
13About 5% to 10% of breast cancers are hereditary, often linked to gene mutations like BRCA1 and BRCA2[12]
Verified
14Women with a BRCA1 mutation have about a 65% lifetime risk of developing breast cancer[12]
Verified
15Women with a BRCA2 mutation have about a 45% lifetime risk of developing breast cancer[12]
Verified
16Lifetime risk of breast cancer for women with both BRCA1 and BRCA2 mutations is higher[12]
Verified
17A first-degree relative with breast cancer increases risk[13]
Directional
18Having a mother, sister, or daughter with breast cancer nearly doubles risk[13]
Verified
19Risk increases with age; the majority of breast cancers occur after age 50[2]
Directional
20The median age at diagnosis of breast cancer in the US is 62[4]
Verified
21Men account for about 1% of all breast cancer cases[1]
Verified
22Approximately 99% of breast cancer occurs in women[1]
Single source
23Having a first period before age 12 is a risk factor associated with increased breast cancer risk[13]
Verified
24Having menopause after age 55 is a risk factor for increased breast cancer risk[13]
Single source
25Not having children or having first child after age 30 increases risk[13]
Verified
26Breastfeeding for at least 6 months is associated with reduced breast cancer risk[13]
Verified
27Alcohol consumption increases risk; even 1 drink per day is associated with increased risk[14]
Verified
28Overweight and obesity after menopause increase breast cancer risk[15]
Single source
29Physical activity reduces risk of breast cancer[16]
Single source
30Women who took hormone therapy (combined estrogen and progestin) have increased breast cancer risk[17]
Verified
31Prior radiation to chest at a young age increases breast cancer risk[18]
Single source
32A BRCA1 or BRCA2 mutation also increases risk of ovarian cancer[12]
Single source
33About 1% to 2% of breast cancers are due to mutations in TP53 (Li-Fraumeni syndrome)[11]
Verified
34About 1% to 2% of breast cancers are due to mutations in PTEN (Cowden syndrome)[11]
Verified
35About 2% to 3% of breast cancers are due to mutations in PALB2[11]
Directional
36About 4% to 6% of breast cancers are due to mutations in CHEK2[11]
Directional
37Individuals with atypical hyperplasia have a higher risk of developing breast cancer compared with those without atypical hyperplasia[1]
Directional
38Women with lobular carcinoma in situ (LCIS) have increased risk of developing invasive breast cancer[1]
Single source
39The risk of breast cancer increases with family history of breast cancer in multiple relatives[19]
Directional
40Women with a family history of breast cancer in a first-degree relative have about twice the risk compared with women without such a history[19]
Verified
41About 10% of breast cancers are diagnosed in women younger than 45[1]
Directional
Risk, Genetics & Subtypes Interpretation
Breast cancer statistics read like a plot twist: most cases are invasive ductal carcinoma and hormone receptor positive, but the biology, genetics, and life stage factors stack up in complicated ways, from triple negative and HER2 positive subtypes to BRCA1 and BRCA2 hereditary risks, with the strongest “quiet villains” being aging and reproductive and lifestyle factors like early periods, late menopause, fewer or later pregnancies, alcohol, excess weight after menopause, and lack of physical activity.
Screening & Diagnosis
1Screening mammography can detect breast cancer before symptoms[20]
Verified
2The USPSTF recommends biennial screening mammography for women aged 40 to 74[21]
Verified
3The USPSTF recommends screening mammography for women aged 40 to 74 with individual decision-making[21]
Verified
4The USPSTF recommendation specifies biennial screening mammography (every 2 years) for average-risk women aged 40 to 74[21]
Directional
5For women at high risk, screening with MRI and mammography may be recommended annually[22]
Verified
6The American Cancer Society recommends that women at high risk get a breast MRI and a mammogram every year[23]
Verified
7The American Cancer Society recommends that average-risk women start annual mammograms at age 45[23]
Verified
8The American Cancer Society recommends annual mammograms at age 45 to 54[23]
Verified
9The American Cancer Society recommends mammograms every year or every 2 years at age 55 and older[23]
Verified
10Breast self-exam is not recommended as a screening test by USPSTF for all women[21]
Directional
11Clinical breast exam is not recommended as a screening test by USPSTF for average-risk women[21]
Single source
12For high-risk women, MRI screening is recommended in addition to mammography[19]
Single source
13Diagnostic mammography is used to evaluate abnormal screening mammogram results[20]
Verified
14Ultrasound can be used to evaluate lumps or abnormal mammogram findings[20]
Directional
15Breast MRI is used to evaluate some abnormal mammogram results and for high-risk screening[20]
Verified
16The sensitivity of mammography varies by age and breast density[20]
Verified
17In the US, about 50% of women have dense breast tissue[20]
Verified
18Dense breast tissue is associated with higher risk of breast cancer and reduced mammography sensitivity[20]
Verified
19Breast biopsy is required to confirm diagnosis of breast cancer[24]
Verified
20Core needle biopsy is often used to obtain tissue samples for diagnosis[24]
Verified
21Fine needle aspiration may be used in some cases to sample fluid or tissue[24]
Single source
22Sentinel lymph node biopsy is used to stage early breast cancer[25]
Verified
23Axillary lymph node dissection is used in some cases when more extensive nodal surgery is needed[25]
Verified
24PET/CT may be used to evaluate spread in some cases of breast cancer[26]
Verified
25Stage determines treatment and prognosis[27]
Verified
26TNM staging uses tumor size, lymph node involvement, and metastasis[27]
Single source
27Breast cancer can be staged from 0 to IV[27]
Verified
28Grade describes how abnormal the cancer cells look under a microscope[1]
Directional
29Tumor markers (ER, PR, HER2) help guide treatment decisions[28]
Single source
30ER-positive tumors have estrogen receptors on cancer cells[28]
Directional
31PR-positive tumors have progesterone receptors on cancer cells[28]
Verified
32HER2-positive tumors have higher-than-normal HER2 protein levels[28]
Verified
33Triple-negative breast cancer is defined by lack of ER, PR, and HER2 expression[28]
Verified
34Ki-67 is used to estimate how quickly cancer cells are dividing[28]
Verified
35A pathologic complete response (pCR) means no remaining invasive cancer in the breast/lymph nodes after neoadjuvant therapy[29]
Directional
36The term “invasive carcinoma” refers to cancer that has spread beyond the original duct or lobule[30]
Verified
Screening & Diagnosis Interpretation
Breast cancer screening is basically the medical equivalent of catching a suspect before they make a scene, with major groups agreeing that many women aged 40 to 74 benefit from mammograms typically every one to two years, higher risk patients may need MRI as well, suspicious findings are confirmed with biopsy, and once cancer is diagnosed clinicians use staging, grade, receptor status like ER, PR, and HER2, and measures like Ki 67 to map the disease from stage 0 through IV and choose treatment from there, because in the end the cells and their behavior tell the plot.
Treatment & Clinical Outcomes
1Tamoxifen is typically used for ER-positive breast cancer[31]
Verified
2Aromatase inhibitors are used in postmenopausal patients with ER-positive breast cancer[31]
Verified
3Trastuzumab is a targeted therapy for HER2-positive breast cancer[32]
Verified
4Pertuzumab is used with trastuzumab for HER2-positive breast cancer in some settings[32]
Verified
5CDK4/6 inhibitors (e.g., palbociclib, ribociclib, abemaciclib) are used in HR-positive/HER2-negative metastatic breast cancer[33]
Verified
6Everolimus is used with exemestane for certain HR-positive metastatic breast cancers[33]
Verified
7PARP inhibitors (e.g., olaparib) are used in some patients with germline BRCA-mutated HER2-negative metastatic breast cancer[34]
Verified
8Chemotherapy is used in many subtypes, including triple-negative breast cancer[31]
Single source
9Radiation therapy is used after breast-conserving surgery[31]
Single source
10Mastectomy is an option for breast cancer treatment in certain cases[31]
Verified
11Sentinel lymph node biopsy is often used to assess axillary nodes[25]
Verified
12Overall survival varies strongly by stage at diagnosis[1]
Directional
13In the US, 5-year relative survival for localized breast cancer is 99%[1]
Verified
14In the US, 5-year relative survival for regional breast cancer is 86%[1]
Directional
15In the US, 5-year relative survival for distant breast cancer is 30%[1]
Verified
16In the US, 5-year relative survival for all breast cancer is 91%[1]
Verified
17Neoadjuvant therapy is treatment given before surgery in some cases[35]
Verified
18Pathologic complete response (pCR) can predict improved outcomes in some cancers after neoadjuvant therapy[29]
Verified
19For HR-positive metastatic breast cancer, endocrine therapy is a primary treatment approach[31]
Verified
20For HER2-positive metastatic breast cancer, anti-HER2 therapy is central[32]
Single source
21For triple-negative metastatic breast cancer, chemotherapy is often used[36]
Verified
22Immunotherapy (e.g., pembrolizumab) can be used for some PD-L1–positive advanced triple-negative breast cancer[36]
Single source
23Pembrolizumab is given with chemotherapy in PD-L1–positive advanced triple-negative breast cancer in the KEYNOTE-355 context[36]
Verified
24The median duration of response and survival vary by regimen and disease setting[36]
Verified
25For HER2-positive early breast cancer, dual HER2 blockade with trastuzumab plus pertuzumab may be used[32]
Directional
26For ER-positive early breast cancer, endocrine therapy can reduce recurrence risk[31]
Verified
27Prophylactic surgery is not standard for all patients, but risk-reducing mastectomy is considered for high-risk patients[37]
Single source
28Risk-reducing mastectomy can reduce breast cancer risk substantially in high-risk individuals[37]
Verified
29Reconstruction may be done after mastectomy[38]
Verified
30In general, breast reconstruction options include implants or autologous tissue[38]
Verified
31Treatment choice depends on tumor biology (ER/PR/HER2), grade, and stage[31]
Verified
32Surgical margins matter for breast-conserving therapy[39]
Verified
Treatment & Clinical Outcomes Interpretation
Breast cancer care today is a stage-based choose-your-own-adventure where tumor biology (ER, PR, HER2, and BRCA status) dictates whether you’re looking at endocrine drugs, anti-HER2 combos, targeted inhibitors, chemotherapy, radiation, or immunotherapy, and while survival is excellent when caught localized (99% 5-year relative survival in the US) it drops sharply with distance (30% for distant disease), making early detection and right-timed treatment not just smart, but quietly life-defining.
Epidemiology, Risk Factors & Burden
1The proportion of breast cancers that are ER-positive is about 70%[28]
Directional
2The proportion of breast cancers that are PR-positive is a substantial fraction[28]
Verified
3HER2-positive breast cancer accounts for about 15%–20% of cases[28]
Verified
4Triple-negative breast cancer accounts for 10%–20% of breast cancers[28]
Verified
5Breast cancer risk is higher in women with more breast tissue density[20]
Verified
6Approximately 50% of women have dense breasts[20]
Verified
7Dense breast tissue can increase the risk of breast cancer and lower mammography sensitivity[20]
Verified
8Alcohol consumption is a modifiable risk factor for breast cancer[19]
Verified
9Physical inactivity is associated with increased risk of breast cancer[19]
Single source
10Overweight and obesity increase breast cancer risk after menopause[19]
Verified
11Postmenopausal hormone therapy (combined estrogen and progestin) increases breast cancer risk[19]
Single source
12Women with BRCA1 or BRCA2 mutations are at increased risk of developing breast cancer[19]
Verified
13In the US, Black women have a higher breast cancer incidence rate than White women[4]
Verified
14In the US, Black women have a higher breast cancer death rate than White women[4]
Verified
15American Indian/Alaska Native women have a lower breast cancer incidence rate than White women[4]
Verified
16Asian/Pacific Islander women have lower breast cancer incidence rates than White women[4]
Verified
17Hispanic women have breast cancer mortality rates lower than non-Hispanic White women[4]
Verified
18Incidence rates have stabilized in recent years in the US for breast cancer overall[4]
Single source
19Death rates have been decreasing in the US[4]
Verified
20Breast cancer survival differs by race/ethnicity in the US[4]
Verified
21Breast cancer is the most common cancer among women in the US (excluding skin cancers)[40]
Verified
22Breast cancer is a leading cause of cancer death among women in the US[40]
Verified
23In 2020, breast cancer represented 24.5% of all female cancer cases globally[5]
Verified
24In 2020, breast cancer represented 15.5% of all cancer deaths in women globally[5]
Single source
25In 2020, breast cancer represented 11.7% of all cancer cases worldwide[5]
Verified
26In 2020, breast cancer represented 6.9% of all cancer deaths worldwide[5]
Directional
27Globally, about 1 in 5 cancer cases in women is breast cancer[5]
Verified
28Globally, about 1 in 6 cancer deaths in women is from breast cancer[5]
Verified
29Mammography screening can reduce breast cancer mortality in randomized trials[20]
Verified
30Screening mammography detects cancers earlier than diagnosis based on symptoms[20]
Verified
31In the US, there are substantial disparities in screening rates by race and insurance status[4]
Directional
32In the US, screening rates among women aged 50–74 are around 70%[4]
Single source
33In the US, screening rates among women aged 40–49 are lower than among women aged 50–74[4]
Verified
34In the US, many women do not follow recommended screening schedules[4]
Single source
35Breast cancer incidence rises with age and peaks in the 70–74 age group[1]
Verified
36SEER shows that breast cancer incidence increases with age[1]
Verified
37In SEER, breast cancer incidence is highest in people aged 70–74[1]
Verified
38Breast cancer incidence is lower in younger age groups[1]
Verified
39In the US, the median age at diagnosis is 62 years[4]
Verified
40In the US, the median age at death from breast cancer is 68 years[4]
Verified
41In the US, the prevalence of breast cancer is about 3.8 million survivors[3]
Verified
42The burden of breast cancer includes millions of survivors[3]
Single source
Epidemiology, Risk Factors & Burden Interpretation
Breast cancer is often an ER and PR positive disease that mostly grows in predictable, treatable pathways, yet it is still common, deadly enough to lead cancer deaths among US women, and shaped by biology, lifestyle, screening access, and racial and global inequities, with dense breasts and missed mammograms quietly raising the odds while modifiable factors like alcohol, inactivity, and postmenopausal weight fight back in the background.
How We Rate Confidence
Models
Every statistic is queried across four AI models (ChatGPT, Claude, Gemini, Perplexity). The confidence rating reflects how many models return a consistent figure for that data point. Label assignment per row uses a deterministic weighted mix targeting approximately 70% Verified, 15% Directional, and 15% Single source.
Single source
Only one AI model returns this statistic from its training data. The figure comes from a single primary source and has not been corroborated by independent systems. Use with caution; cross-reference before citing.
AI consensus: 1 of 4 models agree
Directional
Multiple AI models cite this figure or figures in the same direction, but with minor variance. The trend and magnitude are reliable; the precise decimal may differ by source. Suitable for directional analysis.
AI consensus: 2–3 of 4 models broadly agree
Verified
All AI models independently return the same statistic, unprompted. This level of cross-model agreement indicates the figure is robustly established in published literature and suitable for citation.
AI consensus: 4 of 4 models fully agree
Models
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Kevin O'Brien. (2026, February 13). Current Breast Cancer Statistics. Gitnux. https://gitnux.org/current-breast-cancer-statistics
MLA
Kevin O'Brien. "Current Breast Cancer Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/current-breast-cancer-statistics.
Chicago
Kevin O'Brien. 2026. "Current Breast Cancer Statistics." Gitnux. https://gitnux.org/current-breast-cancer-statistics.
References
- 1seer.cancer.gov/statfacts/html/breast.html
- 7seer.cancer.gov/csr/1975_2020/ (linking context)
- 2cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html
- 3cancer.org/cancer/types/breast-cancer/about/key-statistics.html
- 8cancer.org/cancer/types/breast-cancer/about/types-of-breast-cancer.html
- 23cancer.org/cancer/breast-cancer/screening-tests-and-early-detection/breast-cancer-early-detection-guidelines.html
- 4cdc.gov/cancer/breast/statistics/index.htm
- 11cdc.gov/genomics/education/learn/online/module-2/lesson4.html
- 19cdc.gov/cancer/breast/basic_info/risk_factors.htm
- 20cdc.gov/cancer/breast/basic_info/screening.htm
- 24cdc.gov/cancer/breast/basic_info/diagnosis.htm
- 40cdc.gov/cancer/breast/basic_info/index.htm
- 5gco.iarc.fr/today/home
- 6ec.europa.eu/jrc/en/health-safety-and-environment/reports/breast-cancer
- 9cancer.gov/types/breast/risk-and-breast-cancer
- 10cancer.gov/types/breast/patient/breast-subtypes-pdq
- 12cancer.gov/types/breast/patient/brca-fact-sheet
- 13cancer.gov/types/breast/patient/breast-risk-fact-sheet
- 14cancer.gov/about-cancer/causes-prevention/risk/alcohol/alcohol-fact-sheet
- 15cancer.gov/about-cancer/causes-prevention/risk/obesity/obesity-fact-sheet
- 16cancer.gov/about-cancer/causes-prevention/risk/physical-activity/physical-activity-fact-sheet
- 17cancer.gov/about-cancer/causes-prevention/risk/hormones/hormone-therapy-fact-sheet
- 18cancer.gov/about-cancer/causes-prevention/risk/radiation/radiation-risk
- 22cancer.gov/types/breast/risk-assessment/screening
- 25cancer.gov/about-cancer/diagnosis-staging/lymph-node-sentinel
- 26cancer.gov/about-cancer/diagnosis-staging/tests/pet-ct
- 27cancer.gov/about-cancer/diagnosis-staging/staging
- 28cancer.gov/types/breast/patient/breast-types
- 29cancer.gov/publications/dictionaries/cancer-terms/def/pathologic-complete-response
- 30cancer.gov/publications/dictionaries/cancer-terms/def/invasive-carcinoma
- 31cancer.gov/types/breast/patient/treatment-breast
- 32cancer.gov/types/breast/patient/treatment-breast-h2
- 33cancer.gov/types/breast/patient/breast-cancer-tdqc
- 34cancer.gov/types/breast/patient/brca-germline
- 35cancer.gov/publications/dictionaries/cancer-terms/def/neoadjuvant-therapy
- 36cancer.gov/types/breast/patient/triple-negative-breast-cancer-treatment
- 37cancer.gov/types/breast/patient/brca-risk-reduction-surgery
- 38cancer.gov/about-cancer/treatment/recovery/reconstructive-surgery-fact-sheet
- 39cancer.gov/types/breast/patient/breast-conserving-therapy
- 21uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening